MAPT and Alzheimer disease: In this study, we chose amyloid PET over tau PET, because prior studies [26] suggest that amyloid biomarkers start to appear much earlier compared to tau biomarkers in the AD continuum, and we seek to characterize the multivariate relationships between those early biomarkers and cognition using ML.